MD 69276
CAS No. 29218-27-7
MD 69276( Toloxatone )
Catalog No. M20076 CAS No. 29218-27-7
MD 69276 (Toloxatone) is a reversible monoamine oxidase A (MAOA) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 54 | In Stock |
|
| 2MG | 32 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 170 | In Stock |
|
| 50MG | 272 | In Stock |
|
| 100MG | 456 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMD 69276
-
NoteResearch use only, not for human use.
-
Brief DescriptionMD 69276 (Toloxatone) is a reversible monoamine oxidase A (MAOA) inhibitor.
-
DescriptionMD 69276 (Toloxatone) is a reversible monoamine oxidase A (MAOA) inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsToloxatone
-
PathwayMetabolic Enzyme/Protease
-
TargetMAO
-
RecptorMAO-A
-
Research AreaNeurological Disease
-
IndicationAntidepressant
Chemical Information
-
CAS Number29218-27-7
-
Formula Weight207.23
-
Molecular FormulaC11H13NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 50 mg/mL (241.3 mM)
-
SMILESCc1cccc(c1)N1CC(CO)OC1=O
-
Chemical Name5-(Hydroxymethyl)-3-(3-methylphenyl)-2-oxazolidinone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.FMoureau et al. A reversible monoamine oxidase inhibitor toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD). European Journal of Medicinal Chemistry. 1994 29(4):269-277.
molnova catalog
related products
-
Salvigenin
Salvigenin is a potent hMAO-A inhibitor has neuroprotective antitumor and immunomodulatory effects.
-
PF-9601N
PF-9601N showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD.
-
Amiflamine
Amiflamine is an inhibitor of reversible MAO-A.The ex vivo approach was found to be valid for moclobemide in brain and liver and for cimoxatone in brain tissue;?a slight underestimation of the MAO A inhibitory effect of the latter in the liver is likely.?
Cart
sales@molnova.com